Literature DB >> 2065269

Prognostic factors of alveolar rhabdomyosarcoma in childhood. An International Society of Pediatric Oncology study.

J Reboul-Marty1, E Quintana, V Mosseri, F Flamant, B Asselain, C Rodary, J M Zucker.   

Abstract

Pretreatment characteristics of 57 patients with alveolar rhabdomyosarcoma (RMS) registered by the International Society of Pediatric Oncology (SIOP) between January 1975 and December 1983 were identified to perform a prognostic factor study. Living status and disease-free survival (DFS) time were assessed for all patients on January 1, 1988. By multi-variate analyses, lymph node involvement (P = 0.0003) and tumor invasiveness (P = 0.007) were identified as the most significant covariates correlated with survival. A model including N stage (P = 0.001) and age (P = 0.03) was selected for predicting DFS rates. Children between 5 and 10 years of age had better DFS rates than those younger than 5 years of age or those older than 10 years of age. The authors suggest a prognostic classification that could allow treatment to be adjusted according to clinical staging.

Entities:  

Mesh:

Year:  1991        PMID: 2065269     DOI: 10.1002/1097-0142(19910801)68:3<493::aid-cncr2820680308>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Establishment and characterization of the rhabdomyosarcoma cell line designated NUTOS derived from the human tongue sarcoma: Special reference to the susceptibility of anti-cancer drugs.

Authors:  Minako Suzuki; Noriko Tominaga; Yoshiaki Ide; Akihiro Ohyama; Taka Nakahara; Hiroshi Ishikawa; Akira Tanaka; Izumi Mataga
Journal:  Hum Cell       Date:  2010-05       Impact factor: 4.174

2.  Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  David A Rodeberg; Julie A Stoner; Norbert Garcia-Henriquez; R Lor Randall; Sheri L Spunt; Carola A Arndt; Simon Kao; Charles N Paidas; Lynn Million; Douglas S Hawkins
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.